Molderings G J, Bönisch H, Hammermann R, Göthert M, Brüss M
Institute of Pharmacology and Toxicology, University of Bonn, Reuterstrasse 2b, 53113 Bonn, Germany.
Neurochem Int. 2002 Feb;40(2):157-67. doi: 10.1016/s0197-0186(01)00076-6.
The aim of the present study was to classify release-inhibiting receptors on rat pheochromocytoma PC12 cells. Veratridine-evoked [3H]noradrenaline release from PC12 cells was inhibited by micromolar concentrations of the imidazoline and guanidine derivatives cirazoline, clonidine, aganodine, 1,3-di(2-tolyl)guanidine, BDF6143 and agmatine, and of the cannabinoid receptor agonist WIN55,212-2 (R(+)-2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo-[1,2,3-de]-1,4-benzoxazin-ylmethanone mesylate), but not by noradrenaline. The inhibitory effect of clonidine was antagonized by micromolar concentrations of rauwolscine and SR141716A (N-[piperidin-1-yl]-5-[4-chlorophenyl]-1-[2,4-dichlorophenyl]-4-methyl-1H-pyrazole-3-carboxamide). The potencies of the agonists and antagonists were compatible with an action at previously characterized presynaptic imidazoline receptors. 1-Oleoyl-lysophosphatidic acid, but not sphingosine-1-phosphate, produced an inhibition of release that was antagonized by 30 microM rauwolscine, 1 microM SR141716A and 10 microM LY320135 as well as by pretreatment of the cells with 100 microM clonidine for 72 h. Polymerase chain reaction (PCR) experiments on cDNA from PC12 mRNA suggest mRNA expression of lysophospholipid receptors encoded by the genes edg2, edg3, edg5 and edg7, but not of receptors encoded by edg1, edg4, edg6 and edg8, and not of alpha(2A(-))nd CB(1) receptors. In conclusion, PC12 cells are not endowed with alpha(2)-adrenoceptors and CB(1) cannabinoid receptors, but with an inhibitory receptor recognizing imidazolines, guanidines and WIN55,212-2 similar to that on sympathetic nerves. The PCR results and the ability of 1-oleoyl-LPA to mimic these drugs (also with respect to their susceptibility to antagonists) suggest that the release-inhibiting receptor may be an edg-encoded lysophospholipid receptor.
本研究的目的是对大鼠嗜铬细胞瘤PC12细胞上的释放抑制受体进行分类。微摩尔浓度的咪唑啉和胍衍生物西拉唑啉、可乐定、阿加诺定、1,3 - 二(2 - 甲苯基)胍、BDF6143和胍丁胺,以及大麻素受体激动剂WIN55,212 - 2(R(+)-[2,3 - 二氢 - 5 - 甲基 - 3 - [(吗啉基)甲基]吡咯并 - [1,2,3 - de]-1,4 - 苯并恶嗪 - yl](1 - 萘基)甲酮甲磺酸盐)可抑制藜芦碱诱发的PC12细胞中[3H]去甲肾上腺素的释放,但去甲肾上腺素无此作用。微摩尔浓度的萝芙木碱和SR141716A(N - [哌啶 - 1 - 基]-5 - [4 - 氯苯基]-1 - [2,4 - 二氯苯基]-4 - 甲基 - 1H - 吡唑 - 3 - 甲酰胺)可拮抗可乐定的抑制作用。激动剂和拮抗剂的效能与它们对先前已鉴定的突触前咪唑啉受体的作用相符。1 - 油酰 - 溶血磷脂酸而非鞘氨醇 - 1 - 磷酸可产生释放抑制作用,该作用可被30 μM萝芙木碱、1 μM SR141716A和10 μM LY320135拮抗,也可被用100 μM可乐定预处理细胞72小时所拮抗。对PC12 mRNA的cDNA进行的聚合酶链反应(PCR)实验表明,由edg2、edg3、edg5和edg7基因编码的溶血磷脂受体有mRNA表达,但由edg1、edg4、edg6和edg8基因编码的受体以及α(2A(-))和CB(1)受体无mRNA表达。总之,PC12细胞不具有α(2) - 肾上腺素能受体和CB(1)大麻素受体,而是具有一种识别咪唑啉、胍和WIN55,212 - 2的抑制性受体,类似于交感神经上的受体。PCR结果以及1 - 油酰 - LPA模拟这些药物的能力(也涉及它们对拮抗剂的敏感性)表明,释放抑制受体可能是一种由edg编码的溶血磷脂受体。